{"gene":"CYP21A2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":1988,"finding":"A missense mutation in CYP21B (Ile-172→Asn, codon 172 ATC→AAC) causes steroid 21-hydroxylase deficiency; the mutant gene is expressed in transfected mouse Y1 adrenal cells and produces mRNA but an enzymatically deficient protein, establishing this as a loss-of-function coding mutation.","method":"Site-directed mutagenesis, transfection into mouse Y1 adrenal cells, mRNA expression analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct expression in adrenal cells with functional consequence, foundational result replicated in many subsequent studies","pmids":["3257825"],"is_preprint":false},{"year":1990,"finding":"A 34-nucleotide sequence (-129/-96 bp) in the 5'-flanking region of the human CYP21B gene is required for cAMP-dependent transcription; this element is distinct from the consensus CRE and binds a nuclear protein from adrenal (but not non-adrenal) cells in gel retardation assays, indicating an adrenal-specific transcription factor drives cAMP-dependent CYP21B expression.","method":"Chimeric reporter gene transfection assays (CAT, β-globin reporters), gel retardation/EMSA, cycloheximide inhibition experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter assays, EMSA, protein synthesis inhibitor), replicated in subsequent studies (PMID:1645728, PMID:1334085)","pmids":["2162843"],"is_preprint":false},{"year":1991,"finding":"The cAMP-responsive element of CYP21B (-129/-96 bp) contains two overlapping protein-binding sites: one (-126/-113 bp) binds an adrenal-specific protein (ASP) and the other (-119/-110 bp) binds Sp1. The G→C substitution at -113/-112 bp abolishes binding of both ASP and Sp1 and eliminates cAMP-enhanced transcription. The -126/-113 bp ASP-binding sequence alone is sufficient to confer cAMP-inducible transcription and is functionally conserved in the bovine CYP21B gene.","method":"Gel shift assays (EMSA), site-directed mutagenesis, transient transfection reporter assays, competition analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal EMSA and mutagenesis with functional reporter assay readout in the same study; independently replicated in PMID:1334085","pmids":["1645728"],"is_preprint":false},{"year":1992,"finding":"ASP, the adrenal-specific 78 kDa transcription factor binding the CYP21B cAMP-responsive element (-126/-113 bp), was purified by sequence-specific DNA-affinity chromatography. Antibody against ASP supershifts the DNA-ASP complex and inhibits in vitro transcription. Purified ASP enhances mRNA synthesis from the minimum CRE in a cell-free system, whereas Sp1 does not, establishing ASP as the primary transcription factor for cAMP-dependent CYP21B regulation.","method":"DNA-affinity chromatography purification, EMSA supershift, in vitro transcription assay, DNase I footprinting, SDS-PAGE","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — protein purification, in vitro reconstitution of transcription, footprinting, and antibody inhibition in one study","pmids":["1334085"],"is_preprint":false},{"year":1992,"finding":"The cAMP-responsive sequences (CRS) of CYP21B and CYP17 are distinct from each other and from known CRE consensus sequences; CYP21B CRS binds a putative adrenal-specific nuclear protein, while CYP17 CRSI binds a ubiquitous protein active only in steroidogenic cells, demonstrating that ACTH-dependent co-regulation of these two steroid hydroxylase genes operates through distinct biochemical mechanisms.","method":"Deletion analysis of upstream regulatory regions, nuclear protein binding assays","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — binding assays and deletion analysis, single lab, corroborates PMID:2162843 and PMID:1645728","pmids":["1311271"],"is_preprint":false},{"year":1994,"finding":"CYP21A2 (CYP21B) encodes a microsomal cytochrome P450 enzyme expressed in the adrenal gland that catalyzes conversion of 17-hydroxyprogesterone to 11-deoxycortisol and progesterone to deoxycorticosterone; the degree of enzymatic compromise caused by each mutation is correlated with clinical severity of disease.","method":"Review synthesizing transfection/expression studies and biochemical characterization; genotype-phenotype correlation across patient cohorts","journal":"Human mutation","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic function established by in vitro expression systems across multiple labs; summarized here but underpinned by replicated biochemical experiments","pmids":["8081391"],"is_preprint":false},{"year":1995,"finding":"De novo deletions of CYP21 (approximately 30 kb, breakpoints in intron 2/exon 3) are detected in sperm but not matched leukocyte DNA, occurring at frequencies of ~1/10^5–10^6 genomes, establishing they arise exclusively during meiosis. Gene conversions in the same region occur in both sperm and leukocyte DNA (~1/10^3–10^5 genomes), indicating gene conversions occur during mitosis (or both meiosis and mitosis), a distinct mechanism from unequal crossing-over.","method":"PCR detection of de novo events in matched sperm and leukocyte DNA from normal individuals","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct comparison of sperm vs. somatic DNA with quantitative frequency estimates; mechanistically distinguishes two recombination mechanisms","pmids":["7479886"],"is_preprint":false},{"year":1998,"finding":"The -104G nucleotide in the CYP21 promoter (differing from the CYP21P pseudogene sequence) is required for basal transcription activity; changing -104G to the CYP21P sequence decreases basal transcription by ~80% in transfection assays and abolishes interaction with nuclear proteins from adrenal cells in gel-shift assays.","method":"Transient transfection reporter assay, site-directed mutagenesis, EMSA with adrenal nuclear extracts","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — mutagenesis combined with reporter assay and EMSA, single lab","pmids":["9518489"],"is_preprint":false},{"year":1999,"finding":"Several novel CYP21 mutations (G90V, G291C, R354H, G178A) were functionally characterized by transient transfection in CHOP cells: G90V, G291C, and R354H effectively eliminated 21-hydroxylase activity toward both progesterone and 17α-hydroxyprogesterone, consistent with severe salt-wasting disease; G178A retained significant activity with 17α-hydroxyprogesterone, correlating with the milder simple virilizing phenotype.","method":"In vitro enzyme activity assay in transiently transfected CHOP cells with radiolabeled substrates (progesterone, 17α-hydroxyprogesterone)","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct in vitro enzyme assay with two substrates, single lab","pmids":["10471376"],"is_preprint":false},{"year":2001,"finding":"The IVS2+1G→A splice donor mutation in CYP21 causes generation of two aberrant transcripts when the genomic construct is transfected into COS-1 cells: one lacking exon 2 entirely, and one (~30% of transcripts) with inclusion of 3' intron 2 sequences due to use of a cryptic splice acceptor site, resulting in a non-functional protein.","method":"Transfection of CYP21 genomic construct into COS-1 cells, RT-PCR analysis of transcripts","journal":"The Journal of endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct transcript analysis after transfection, single lab, mechanistically defines splicing consequences of IVS2+1G→A","pmids":["11739005"],"is_preprint":false},{"year":2002,"finding":"The novel CYP21 missense mutation V304M shows 46% residual enzyme activity for 17-hydroxyprogesterone and 26% for progesterone conversion in COS-1 cells, with normal protein degradation, indicating a functional rather than structural defect consistent with nonclassical disease. G375S nearly abolishes enzyme activity (1.6% and 0.7% of normal for both substrates), consistent with classical disease.","method":"In vitro enzyme activity assay in transiently transfected COS-1 cells with both natural substrates; protein degradation analysis","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct in vitro enzyme assay with two substrates plus protein stability assessment, single lab","pmids":["12050257"],"is_preprint":false},{"year":2006,"finding":"Four novel CYP21 missense mutations (L166P, A391T, R479L, R483Q) were characterized by in vitro enzyme assay in transiently transfected mammalian cells; all showed reduced activity compared to wild-type for both natural substrates (17-hydroxyprogesterone and progesterone), spanning the full spectrum of disease severity from severe to mild.","method":"In vitro enzyme activity assay in transfected mammalian cells with radiolabeled 17-hydroxyprogesterone and progesterone","journal":"Journal of molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct enzyme assay with two substrates, single lab","pmids":["17119906"],"is_preprint":false},{"year":2007,"finding":"Microconversions between the CYP21A2 and CYP21A1P promoter regions (-126C>T, -113G>A, -110T>C) reduce CYP21A2 transcriptional activity to 52% of wild-type in luciferase reporter assays, contributing to the nonclassical CAH phenotype. EMSA demonstrated that the -132/-121 region is critical for interaction with the Sp1 transcription factor.","method":"Luciferase reporter transfection assays, EMSA with NCI-H295A nuclear extracts and wild-type/mutant probes, direct DNA sequencing","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — orthogonal reporter assay and EMSA, single lab","pmids":["17666484"],"is_preprint":false},{"year":2008,"finding":"Three novel CYP21A2 mutations (p.G56R, p.L107R, p.L142P) and one recurrent mutation (p.R408C) were characterized by in vitro activity assay in transiently transfected COS-1 cells; all showed very low residual activity (<5% for both substrates), classifying them as classical CAH mutations. p.H62L showed activity within the nonclassical range; p.H62L+p.P453S in combination showed a synergistic reduction in activity greater than either alone.","method":"In vitro enzyme activity assay in transiently transfected COS-1 cells; apparent kinetic constants (Km) determined for H62L mutant","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — kinetic characterization plus activity assay with two substrates, single lab","pmids":["18381579"],"is_preprint":false},{"year":2008,"finding":"The novel CYP21A2 mutation K121Q (located on helix C) reduces 21-hydroxylase activity to ~14–19% of normal in transfected COS-7 cells. Protein modeling reveals K121 is in the heme-coordinating system and on the surface involved in P450 oxidoreductase interaction, suggesting the mutation impairs electron flux from P450 oxidoreductase to CYP21A2 and alters substrate affinity via heme dislocation.","method":"In vitro expression in transiently transfected COS-7 cells, homology-based 3D protein modeling","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct in vitro enzyme assay plus structural modeling, single lab; modeling is computational but supports mechanistic inference","pmids":["18445671"],"is_preprint":false},{"year":2008,"finding":"p.H62L alone reduces CYP21 enzyme activity similarly to the mild p.P453S mutation (nonclassical range); when p.H62L is combined with p.P453S on the same allele, enzymatic activity is synergistically reduced to a level intermediate between p.P453S and p.I172N. 3D modeling locates H62 in a domain involved in membrane anchoring.","method":"In vitro enzyme activity assay in transfected cells; 3D protein model analysis; phenotype correlation","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct enzyme assay demonstrating synergistic effect, single lab","pmids":["18319307"],"is_preprint":false},{"year":2012,"finding":"1α,25-Dihydroxyvitamin D3 suppresses CYP21A2 transcription via a vitamin D receptor (VDR)-mediated mechanism. A vitamin D response element was identified in the CYP21A2 promoter; interaction of this element with VDR, WSTF, and VDIR comodulators was confirmed by chromatin immunoprecipitation. Deletion of this element abolished the vitamin D effect; siRNA knockdown of VDIR confirmed its involvement. An altered balance of comodulators can reverse the suppressive effect to stimulatory.","method":"Luciferase reporter assays with promoter deletion constructs, chromatin immunoprecipitation (ChIP), site-directed mutagenesis, siRNA knockdown","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (reporter assay, ChIP, mutagenesis, siRNA) in a single study","pmids":["22561756"],"is_preprint":false},{"year":2013,"finding":"Using a humanized homology model of CYP21A2 based on the bovine crystal structure, CYP21A2 mutations causing complete loss of function (salt-wasting disease) affect membrane anchoring, heme/substrate binding, or protein stability; mutations causing simple virilizing disease alter the transmembrane region or conserved hydrophobic patches (up to 98% activity reduction); mild nonclassical disease results from interference with oxidoreductase interactions, salt-bridge/hydrogen-bonding networks, or nonconserved hydrophobic clusters.","method":"Computational structure-function modeling based on bovine CYP21 crystal structure; comprehensive mapping of >100 disease-causing mutations onto 3D model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — structural/computational model with systematic coverage of >100 mutations correlated to known biochemical activity data; no direct in vitro validation of new mutations in this paper","pmids":["23359706"],"is_preprint":false},{"year":2015,"finding":"A CYP21A2-based whole-cell biocatalytic system in E. coli (co-expressing bovine CYP21A2 with NADPH-dependent cytochrome P450 reductase, CPR, via a bicistronic vector) selectively 21-hydroxylates the synthetic substrate medrane to premedrol, demonstrating that CYP21A2 requires CPR as its redox partner for electron supply, and that the catalytic yield is directly dependent on the efficiency of the electron transfer system.","method":"Whole-cell biotransformation in E. coli; bicistronic co-expression of CYP21A2 and CPR; comparison of five alternative redox systems; bioreactor optimization","journal":"Microbial cell factories","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted enzymatic system with defined redox partner, multiple redox partner comparisons, bioreactor validation","pmids":["26374204"],"is_preprint":false},{"year":2019,"finding":"CYP21A2 requires a 3-oxo group at C-3 of the steroid substrate as a strict requirement for catalytic activity; all other ring A configurations tested (hydroxyl, oxo, fluoro, chloro groups; presence/absence of Δ1 and Δ4 double bonds; heteroatoms) were tolerated. Progesterone and 17-hydroxyprogesterone are hydroxylated at C-21, whereas (17-hydroxy-)pregnenolone (lacking the 3-oxo group) is not a substrate. Molecular docking suggests the C-3 carbonyl interacts indispensably with Arg234 in the active site.","method":"In vitro enzyme activity assay with sixteen synthetic 17,17-dimethyl-18-nor-13-ene steroid substrates plus endogenous steroids; molecular docking","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — comprehensive substrate specificity mapping with 16+ substrates in biochemical assay plus structural docking, single lab but multiple orthogonal lines of evidence","pmids":["31404637"],"is_preprint":false}],"current_model":"CYP21A2 encodes a microsomal cytochrome P450 enzyme that catalyzes the NADPH-dependent (via P450 oxidoreductase as its electron donor) 21-hydroxylation of progesterone to deoxycorticosterone and 17-hydroxyprogesterone to 11-deoxycortisol in the adrenal cortex; catalysis requires a 3-oxo group at C-3 of the substrate, which interacts with active-site residue Arg234; adrenal-specific, cAMP-dependent transcription is driven by an adrenal-specific 78 kDa transcription factor (ASP) binding a unique promoter element (-126/-113 bp), with Sp1 as a co-occupant, and is further modulated by 1α,25-dihydroxyvitamin D3 through a VDR/VDIR/WSTF comodulator mechanism at a distinct promoter response element; disease-causing mutations spanning salt-wasting to nonclassical phenotypes act by disrupting membrane anchoring, heme/substrate binding, protein stability, oxidoreductase interaction surfaces, or structural integrity of the active site."},"narrative":{"mechanistic_narrative":"CYP21A2 encodes a microsomal cytochrome P450 enzyme of the adrenal cortex that catalyzes the 21-hydroxylation of progesterone to deoxycorticosterone and of 17-hydroxyprogesterone to 11-deoxycortisol, the committed step routing steroid precursors toward mineralocorticoid and glucocorticoid synthesis [PMID:8081391]. Catalysis depends on a strict structural requirement of the substrate—a 3-oxo group at C-3 of ring A, which docking places in indispensable contact with the active-site residue Arg234, while other ring A configurations are tolerated [PMID:31404637]. The enzyme operates as the terminal oxidase of a two-component system, drawing electrons from NADPH-dependent cytochrome P450 reductase (CPR) as its obligate redox partner, with catalytic output scaling directly with electron-transfer efficiency [PMID:26374204]. Adrenal-restricted, cAMP-responsive transcription is driven through a unique promoter element (-126/-113 bp) bound by a purified 78 kDa adrenal-specific protein (ASP), which alone is sufficient to confer cAMP-inducible transcription and to enhance mRNA synthesis in vitro, with Sp1 occupying an overlapping adjacent site [PMID:1645728, PMID:1334085]; transcription is further modulated by 1α,25-dihydroxyvitamin D3 through a promoter response element engaging VDR, WSTF, and VDIR comodulators [PMID:22561756]. Loss-of-function mutations across the gene cause steroid 21-hydroxylase deficiency, and the degree of enzymatic compromise measured in expression assays correlates with clinical severity from salt-wasting through simple virilizing to nonclassical phenotypes [PMID:8081391, PMID:3257825]; structure-function mapping attributes these effects to disruption of membrane anchoring, heme/substrate binding, protein stability, oxidoreductase interaction surfaces, or active-site integrity [PMID:23359706].","teleology":[{"year":1988,"claim":"Established that a single coding missense change in CYP21 produces a stable but catalytically deficient enzyme, defining 21-hydroxylase deficiency as a loss-of-function disorder rather than a regulatory or expression defect.","evidence":"Site-directed mutagenesis of Ile-172→Asn expressed in transfected mouse Y1 adrenal cells with mRNA and activity analysis","pmids":["3257825"],"confidence":"High","gaps":["Did not resolve which structural feature of the enzyme the residue maintains","Single mutation; spectrum of allelic effects not yet mapped"]},{"year":1990,"claim":"Identified the cis element responsible for adrenal-specific, cAMP-driven CYP21 expression, showing it is distinct from canonical CRE and bound by an adrenal-restricted nuclear factor.","evidence":"Chimeric reporter transfection, EMSA with adrenal vs. non-adrenal extracts, and cycloheximide inhibition","pmids":["2162843"],"confidence":"High","gaps":["Binding factor not yet purified or identified","Relationship to general cAMP signaling machinery unresolved"]},{"year":1991,"claim":"Dissected the cAMP-responsive region into overlapping ASP and Sp1 binding sites and showed the ASP site alone suffices for cAMP induction, separating the adrenal-specific factor from the ubiquitous Sp1.","evidence":"EMSA, site-directed mutagenesis (G→C at -113/-112), and competition reporter assays, with bovine conservation","pmids":["1645728"],"confidence":"High","gaps":["ASP identity remained unknown","Mechanistic link between cAMP signaling and ASP activity not defined"]},{"year":1992,"claim":"Purified the 78 kDa adrenal-specific protein ASP and demonstrated it directly drives transcription from the minimal CRE in a cell-free system, establishing it as the primary determinant of cAMP-dependent CYP21 regulation over Sp1.","evidence":"DNA-affinity purification, EMSA supershift, in vitro transcription, DNase I footprinting; parallel deletion analysis distinguishing CYP21 from CYP17 regulation","pmids":["1334085","1311271"],"confidence":"High","gaps":["Gene encoding ASP not cloned","Signaling cascade coupling ACTH/cAMP to ASP function unresolved"]},{"year":1994,"claim":"Consolidated CYP21A2 as a microsomal adrenal P450 converting progesterone and 17-hydroxyprogesterone, and articulated the genotype-phenotype principle that residual enzymatic activity predicts disease severity.","evidence":"Review synthesizing transfection/expression and biochemical studies with cohort genotype-phenotype correlation","pmids":["8081391"],"confidence":"High","gaps":["Structural basis of activity loss for individual mutations not yet defined","Redox partner requirement not directly demonstrated"]},{"year":1995,"claim":"Distinguished the two mutational mechanisms underlying CYP21 deficiency, showing large deletions arise in meiosis while gene conversions also occur mitotically.","evidence":"PCR detection of de novo events in matched sperm vs. leukocyte DNA from normal individuals with frequency estimation","pmids":["7479886"],"confidence":"High","gaps":["Molecular determinants of recombination hotspots not defined","Does not address point mutation origins"]},{"year":1998,"claim":"Showed that a single promoter nucleotide distinguishing CYP21A2 from its pseudogene controls basal transcription and adrenal nuclear protein binding, linking pseudogene-derived microconversions to expression defects.","evidence":"Reporter assay, site-directed mutagenesis, and EMSA with adrenal extracts","pmids":["9518489"],"confidence":"Medium","gaps":["Single lab","Identity of the bound nuclear protein not established"]},{"year":2002,"claim":"Demonstrated that mutations can impair catalysis without destabilizing the protein, defining a functional (active-site) versus structural (degradation) basis for milder versus severe phenotypes.","evidence":"In vitro activity assays with both substrates plus protein degradation analysis in COS-1 cells (V304M vs. G375S)","pmids":["12050257"],"confidence":"Medium","gaps":["Single lab","Limited to two mutations"]},{"year":2008,"claim":"Mapped specific mutations to functional domains—membrane anchoring, the heme-coordinating system, and the P450 oxidoreductase interaction surface—and revealed synergistic activity loss when mild variants co-occur in cis.","evidence":"In vitro activity/kinetic assays in COS cells combined with homology-based 3D modeling (K121Q, H62L, P453S and others)","pmids":["18445671","18319307","18381579"],"confidence":"Medium","gaps":["Modeling-based domain assignments not directly validated biochemically","Single-lab activity measurements"]},{"year":2012,"claim":"Identified vitamin D as a transcriptional modulator of CYP21A2, acting through a defined promoter response element and VDR/WSTF/VDIR comodulators whose balance can switch the effect between repressive and stimulatory.","evidence":"Reporter deletion constructs, ChIP, site-directed mutagenesis, and VDIR siRNA knockdown","pmids":["22561756"],"confidence":"High","gaps":["Physiological significance of vitamin D regulation in vivo not established","Interplay with the cAMP/ASP axis unresolved"]},{"year":2013,"claim":"Provided a unifying structural framework correlating mutation location with phenotype, attributing salt-wasting, simple virilizing, and nonclassical disease to distinct classes of structural perturbation.","evidence":"Computational structure-function mapping of >100 mutations onto a humanized homology model from the bovine CYP21 crystal structure","pmids":["23359706"],"confidence":"Medium","gaps":["No direct in vitro validation of newly classified mutations in this work","Predictions for individual variants require experimental confirmation"]},{"year":2018,"claim":"Defined the obligate redox dependency of CYP21A2 by reconstituting catalysis with CPR and showing that yield tracks electron-transfer efficiency, confirming CPR as the physiological electron donor.","evidence":"Whole-cell E. coli biotransformation with bicistronic CYP21A2/CPR co-expression and comparison of five redox systems","pmids":["26374204"],"confidence":"High","gaps":["Performed with bovine enzyme and a synthetic substrate","Quantitative coupling parameters in native adrenal microsomes not measured"]},{"year":2019,"claim":"Defined the precise substrate determinant of catalysis—an obligatory C-3 oxo group engaging Arg234—explaining why progesterone and 17-hydroxyprogesterone are substrates while pregnenolone is not.","evidence":"In vitro activity assays with 16 synthetic steroid analogs plus endogenous steroids and molecular docking","pmids":["31404637"],"confidence":"High","gaps":["Arg234 contact inferred from docking, not crystallography","Catalytic mechanism of hydroxyl transfer not directly resolved"]},{"year":null,"claim":"The molecular identity of the adrenal-specific transcription factor ASP and how ACTH/cAMP signaling is mechanistically transduced to activate it remain unresolved in the available corpus.","evidence":"No discovery cloning or molecularly identifying ASP is present in the timeline","pmids":[],"confidence":"Medium","gaps":["ASP gene not identified","Signaling pathway from cAMP to ASP activity undefined","No experimental crystal structure of human CYP21A2"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[5,18,19]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[5,19]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,16]}],"complexes":[],"partners":["POR","SP1","VDR","VDIR","WSTF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08686","full_name":"Steroid 21-hydroxylase","aliases":["21-OHase","Cytochrome P-450c21","Cytochrome P450 21","Cytochrome P450 XXI","Cytochrome P450-C21","Cytochrome P450-C21B"],"length_aa":495,"mass_kda":56.0,"function":"A cytochrome P450 monooxygenase that plays a major role in adrenal steroidogenesis. Catalyzes the hydroxylation at C-21 of progesterone and 17alpha-hydroxyprogesterone to respectively form 11-deoxycorticosterone and 11-deoxycortisol, intermediate metabolites in the biosynthetic pathway of mineralocorticoids and glucocorticoids (PubMed:10602386, PubMed:16984992, PubMed:22014889, PubMed:25855791, PubMed:27721825). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:25855791)","subcellular_location":"Endoplasmic reticulum membrane; Microsome membrane","url":"https://www.uniprot.org/uniprotkb/P08686/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP21A2","classification":"Not Classified","n_dependent_lines":15,"n_total_lines":1208,"dependency_fraction":0.012417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP21A2","total_profiled":1310},"omim":[{"mim_id":"615549","title":"ARMADILLO REPEAT-CONTAINING PROTEIN 5; ARMC5","url":"https://www.omim.org/entry/615549"},{"mim_id":"613815","title":"CYTOCHROME P450, FAMILY 21, SUBFAMILY A, POLYPEPTIDE 2; CYP21A2","url":"https://www.omim.org/entry/613815"},{"mim_id":"609300","title":"CYTOCHROME P450, FAMILY 17, SUBFAMILY A, POLYPEPTIDE 1; CYP17A1","url":"https://www.omim.org/entry/609300"},{"mim_id":"607397","title":"MELANOCORTIN 2 RECEPTOR; MC2R","url":"https://www.omim.org/entry/607397"},{"mim_id":"606408","title":"EHLERS-DANLOS SYNDROME, CLASSIC-LIKE, 1; EDSCLL1","url":"https://www.omim.org/entry/606408"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"adrenal gland","ntpm":2046.8}],"url":"https://www.proteinatlas.org/search/CYP21A2"},"hgnc":{"alias_symbol":["P450c21B","CA21H","CPS1","CAH1"],"prev_symbol":["CYP21","CYP21B"]},"alphafold":{"accession":"P08686","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08686","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08686-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08686-F1-predicted_aligned_error_v6.png","plddt_mean":92.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP21A2","jax_strain_url":"https://www.jax.org/strain/search?query=CYP21A2"},"sequence":{"accession":"P08686","fasta_url":"https://rest.uniprot.org/uniprotkb/P08686.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08686/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08686"}},"corpus_meta":[{"pmid":"7686164","id":"PMC_7686164","title":"Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7686164","citation_count":277,"is_preprint":false},{"pmid":"3257825","id":"PMC_3257825","title":"Mutation in the CYP21B gene (Ile-172----Asn) causes steroid 21-hydroxylase deficiency.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3257825","citation_count":226,"is_preprint":false},{"pmid":"8675607","id":"PMC_8675607","title":"ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin.","date":"1996","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/8675607","citation_count":186,"is_preprint":false},{"pmid":"10859342","id":"PMC_10859342","title":"Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10859342","citation_count":155,"is_preprint":false},{"pmid":"1985465","id":"PMC_1985465","title":"Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency.","date":"1991","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1985465","citation_count":148,"is_preprint":false},{"pmid":"10207042","id":"PMC_10207042","title":"Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10207042","citation_count":148,"is_preprint":false},{"pmid":"12915679","id":"PMC_12915679","title":"CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12915679","citation_count":139,"is_preprint":false},{"pmid":"7479886","id":"PMC_7479886","title":"Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7479886","citation_count":139,"is_preprint":false},{"pmid":"8081391","id":"PMC_8081391","title":"Mutations in steroid 21-hydroxylase (CYP21).","date":"1994","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/8081391","citation_count":103,"is_preprint":false},{"pmid":"23359706","id":"PMC_23359706","title":"Structure-phenotype correlations of human CYP21A2 mutations in congenital adrenal hyperplasia.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/23359706","citation_count":95,"is_preprint":false},{"pmid":"8733045","id":"PMC_8733045","title":"Direct molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia.","date":"1996","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8733045","citation_count":91,"is_preprint":false},{"pmid":"11223087","id":"PMC_11223087","title":"Partial purification and characterization of a hemolysin (CAH1) from Hawaiian box jellyfish (Carybdea alata) venom.","date":"2001","source":"Toxicon : official journal of the International Society on Toxinology","url":"https://pubmed.ncbi.nlm.nih.gov/11223087","citation_count":86,"is_preprint":false},{"pmid":"10084579","id":"PMC_10084579","title":"Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10084579","citation_count":86,"is_preprint":false},{"pmid":"29035424","id":"PMC_29035424","title":"CYP21A2 mutation update: Comprehensive analysis of databases and published genetic variants.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/29035424","citation_count":80,"is_preprint":false},{"pmid":"2162843","id":"PMC_2162843","title":"cAMP-dependent transcription of the human CYP21B (P-450C21) gene requires a cis-regulatory element distinct from the consensus cAMP-regulatory element.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2162843","citation_count":79,"is_preprint":false},{"pmid":"29450859","id":"PMC_29450859","title":"Congenital Adrenal Hyperplasia (CAH) due to 21-Hydroxylase Deficiency: A Comprehensive Focus on 233 Pathogenic Variants of CYP21A2 Gene.","date":"2018","source":"Molecular diagnosis & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29450859","citation_count":75,"is_preprint":false},{"pmid":"15155888","id":"PMC_15155888","title":"The novel Myb transcription factor LCR1 regulates the CO2-responsive gene Cah1, encoding a periplasmic carbonic anhydrase in Chlamydomonas reinhardtii.","date":"2004","source":"The Plant cell","url":"https://pubmed.ncbi.nlm.nih.gov/15155888","citation_count":74,"is_preprint":false},{"pmid":"2325662","id":"PMC_2325662","title":"Direct analysis of CYP21B genes in 21-hydroxylase deficiency using polymerase chain reaction amplification.","date":"1990","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/2325662","citation_count":74,"is_preprint":false},{"pmid":"10323382","id":"PMC_10323382","title":"High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche.","date":"1999","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/10323382","citation_count":70,"is_preprint":false},{"pmid":"14671153","id":"PMC_14671153","title":"CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/14671153","citation_count":68,"is_preprint":false},{"pmid":"12226794","id":"PMC_12226794","title":"Genetic sophistication of human complement components C4A and C4B and RP-C4-CYP21-TNX (RCCX) modules in the major histocompatibility complex.","date":"2002","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12226794","citation_count":63,"is_preprint":false},{"pmid":"28396394","id":"PMC_28396394","title":"The carbonic anhydrase CAH1 is an essential component of the carbon-concentrating mechanism in Nannochloropsis oceanica.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28396394","citation_count":59,"is_preprint":false},{"pmid":"11397897","id":"PMC_11397897","title":"The spectrum of molecular defects of the CYP21 gene in the Hellenic population: variable concordance between genotype and phenotype in the different forms of congenital adrenal hyperplasia.","date":"2001","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11397897","citation_count":57,"is_preprint":false},{"pmid":"17666484","id":"PMC_17666484","title":"Microconversion between CYP21A2 and CYP21A1P promoter regions causes the nonclassical form of 21-hydroxylase deficiency.","date":"2007","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17666484","citation_count":55,"is_preprint":false},{"pmid":"18381579","id":"PMC_18381579","title":"Inhibition of CYP21A2 enzyme activity caused by novel missense mutations identified in Brazilian and Scandinavian patients.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18381579","citation_count":54,"is_preprint":false},{"pmid":"12384784","id":"PMC_12384784","title":"Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes.","date":"2002","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12384784","citation_count":53,"is_preprint":false},{"pmid":"1645728","id":"PMC_1645728","title":"Evidence that an adrenal-specific nuclear protein regulates the cAMP responsiveness of the human CYP21B (P450C21) gene.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1645728","citation_count":51,"is_preprint":false},{"pmid":"15081125","id":"PMC_15081125","title":"PCR-based detection of the CYP21 deletion and TNXA/TNXB hybrid in the RCCX module.","date":"2004","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/15081125","citation_count":49,"is_preprint":false},{"pmid":"11359457","id":"PMC_11359457","title":"CYP21 mutations and congenital adrenal hyperplasia.","date":"2001","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11359457","citation_count":48,"is_preprint":false},{"pmid":"10398710","id":"PMC_10398710","title":"Periplasmic carbonic anhydrase structural gene (Cah1) mutant in chlamydomonas reinhardtii.","date":"1999","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10398710","citation_count":48,"is_preprint":false},{"pmid":"14604014","id":"PMC_14604014","title":"Dancing with complement C4 and the RP-C4-CYP21-TNX (RCCX) modules of the major histocompatibility complex.","date":"2003","source":"Progress in nucleic acid research and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14604014","citation_count":46,"is_preprint":false},{"pmid":"12050257","id":"PMC_12050257","title":"Novel mutations in CYP21 detected in individuals with hyperandrogenism.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12050257","citation_count":46,"is_preprint":false},{"pmid":"2613228","id":"PMC_2613228","title":"Two distinct areas of unequal crossingover within the steroid 21-hydroxylase genes produce absence of CYP21B.","date":"1989","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2613228","citation_count":43,"is_preprint":false},{"pmid":"16712666","id":"PMC_16712666","title":"Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.","date":"2006","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/16712666","citation_count":43,"is_preprint":false},{"pmid":"11117678","id":"PMC_11117678","title":"The role of heterozygosity for CYP21 in the polycystic ovary syndrome.","date":"2000","source":"Journal of pediatric endocrinology & metabolism : JPEM","url":"https://pubmed.ncbi.nlm.nih.gov/11117678","citation_count":42,"is_preprint":false},{"pmid":"24071710","id":"PMC_24071710","title":"Comprehensive mutation analysis of the CYP21A2 gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia.","date":"2013","source":"The Journal of molecular diagnostics : JMD","url":"https://pubmed.ncbi.nlm.nih.gov/24071710","citation_count":42,"is_preprint":false},{"pmid":"14555782","id":"PMC_14555782","title":"Cis-acting elements and DNA-binding proteins involved in CO2-responsive transcriptional activation of Cah1 encoding a periplasmic carbonic anhydrase in Chlamydomonas reinhardtii.","date":"2003","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14555782","citation_count":40,"is_preprint":false},{"pmid":"8589688","id":"PMC_8589688","title":"A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element?","date":"1995","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8589688","citation_count":40,"is_preprint":false},{"pmid":"15705377","id":"PMC_15705377","title":"Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess.","date":"2005","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/15705377","citation_count":37,"is_preprint":false},{"pmid":"28323907","id":"PMC_28323907","title":"Resveratrol inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28323907","citation_count":36,"is_preprint":false},{"pmid":"14730433","id":"PMC_14730433","title":"The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency.","date":"2004","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14730433","citation_count":35,"is_preprint":false},{"pmid":"10229037","id":"PMC_10229037","title":"Mutation distribution and CYP21/C4 locus variability in Brazilian families with the classical form of the 21-hydroxylase deficiency.","date":"1999","source":"Acta paediatrica (Oslo, Norway : 1992)","url":"https://pubmed.ncbi.nlm.nih.gov/10229037","citation_count":35,"is_preprint":false},{"pmid":"21274396","id":"PMC_21274396","title":"CYP21A2 gene mutations in congenital adrenal hyperplasia: genotype-phenotype correlation in Turkish children.","date":"2009","source":"Journal of clinical research in pediatric endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21274396","citation_count":35,"is_preprint":false},{"pmid":"21646284","id":"PMC_21646284","title":"Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche.","date":"2011","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21646284","citation_count":35,"is_preprint":false},{"pmid":"10594120","id":"PMC_10594120","title":"CO(2)-responsive transcriptional regulation of CAH1 encoding carbonic anhydrase is mediated by enhancer and silencer regions in Chlamydomonas reinhardtii.","date":"1999","source":"Plant physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10594120","citation_count":34,"is_preprint":false},{"pmid":"8980526","id":"PMC_8980526","title":"Circadian expression of the carbonic anhydrase gene, Cah1, in Chlamydomonas reinhardtii.","date":"1996","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8980526","citation_count":33,"is_preprint":false},{"pmid":"1311271","id":"PMC_1311271","title":"Distinct biochemical mechanisms for cAMP-dependent transcription of CYP17 and CYP21.","date":"1992","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/1311271","citation_count":32,"is_preprint":false},{"pmid":"8731325","id":"PMC_8731325","title":"Molecular analysis of CYP21 and C4 genes in Brazilian families with the classical form of steroid 21-hydroxylase deficiency.","date":"1996","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/8731325","citation_count":31,"is_preprint":false},{"pmid":"9745454","id":"PMC_9745454","title":"Salt-wasting congenital adrenal hyperplasia: detection of mutations in CYP21B gene in a Chilean population.","date":"1998","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/9745454","citation_count":31,"is_preprint":false},{"pmid":"2109953","id":"PMC_2109953","title":"The swine steroid 21-hydroxylase gene (CYP21): cloning and mapping within the swine leucocyte antigen complex.","date":"1990","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2109953","citation_count":31,"is_preprint":false},{"pmid":"14502362","id":"PMC_14502362","title":"Phenotype and genotype correlation of the microconversion from the CYP21A1P to the CYP21A2 gene in congenital adrenal hyperplasia.","date":"2003","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/14502362","citation_count":31,"is_preprint":false},{"pmid":"15639189","id":"PMC_15639189","title":"Chimeric CYP21P/CYP21 and TNXA/TNXB genes in the RCCX module.","date":"2004","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15639189","citation_count":30,"is_preprint":false},{"pmid":"18319307","id":"PMC_18319307","title":"p.H62L, a rare mutation of the CYP21 gene identified in two forms of 21-hydroxylase deficiency.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18319307","citation_count":30,"is_preprint":false},{"pmid":"12050231","id":"PMC_12050231","title":"Genetic analysis of Japanese patients with 21-hydroxylase deficiency: identification of a patient with a new mutation of a homozygous deletion of adenine at codon 246 and patients without demonstrable mutations within the structural gene for CYP21.","date":"2002","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12050231","citation_count":30,"is_preprint":false},{"pmid":"1334085","id":"PMC_1334085","title":"Purification and characterization of a transcription factor which appears to regulate cAMP responsiveness of the human CYP21B gene.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1334085","citation_count":29,"is_preprint":false},{"pmid":"25609776","id":"PMC_25609776","title":"Abundance of DLK1, differential expression of CYP11B1, CYP21A2 and MC2R, and lack of INSL3 distinguish testicular adrenal rest tumours from Leydig cell tumours.","date":"2015","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25609776","citation_count":28,"is_preprint":false},{"pmid":"21324303","id":"PMC_21324303","title":"Analysis of the CYP21A1P pseudogene: indication of mutational diversity and CYP21A2-like and duplicated CYP21A2 genes.","date":"2011","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21324303","citation_count":27,"is_preprint":false},{"pmid":"17119906","id":"PMC_17119906","title":"Characterization of novel missense mutations in CYP21 causing congenital adrenal hyperplasia.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/17119906","citation_count":27,"is_preprint":false},{"pmid":"11093272","id":"PMC_11093272","title":"CYP21 and CYP21P variability in steroid 21-hydroxylase deficiency patients and in the general population in the Netherlands.","date":"2000","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/11093272","citation_count":25,"is_preprint":false},{"pmid":"22017335","id":"PMC_22017335","title":"Mutation analysis of the CYP21A2 gene in the Iranian population.","date":"2011","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/22017335","citation_count":25,"is_preprint":false},{"pmid":"10794740","id":"PMC_10794740","title":"Analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency.","date":"2000","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10794740","citation_count":25,"is_preprint":false},{"pmid":"10343159","id":"PMC_10343159","title":"An unequal crossover between the RCCX modules of the human MHC leading to the presence of a CYP21B gene and a tenascin TNXB/TNXA-RP2 recombinant between C4A and C4B genes in a patient with juvenile rheumatoid arthritis.","date":"1999","source":"Experimental and clinical immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10343159","citation_count":24,"is_preprint":false},{"pmid":"22629504","id":"PMC_22629504","title":"Molecular genetic analysis of CYP21A2 gene in patients with congenital adrenal hyperplasia.","date":"2012","source":"Indian journal of endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/22629504","citation_count":24,"is_preprint":false},{"pmid":"20838032","id":"PMC_20838032","title":"Molecular defects of the CYP21A2 gene in Greek-Cypriot patients with congenital adrenal hyperplasia.","date":"2010","source":"Hormone research in paediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/20838032","citation_count":23,"is_preprint":false},{"pmid":"12174671","id":"PMC_12174671","title":"Molecular diagnosis of CYP21 mutations in congenital adrenal hyperplasia: implications for genetic counseling.","date":"2001","source":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/12174671","citation_count":22,"is_preprint":false},{"pmid":"12376740","id":"PMC_12376740","title":"Structural analysis of the chimeric CYP21P/CYP21 gene in steroid 21-hydroxylase deficiency.","date":"2002","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12376740","citation_count":22,"is_preprint":false},{"pmid":"8093607","id":"PMC_8093607","title":"Organization and evolution of C4 and CYP21 genes in primates: importance of genomic segments.","date":"1993","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8093607","citation_count":20,"is_preprint":false},{"pmid":"15110320","id":"PMC_15110320","title":"Detection and assignment of CYP21 mutations using peptide mass signature genotyping.","date":"2004","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15110320","citation_count":20,"is_preprint":false},{"pmid":"26374204","id":"PMC_26374204","title":"A CYP21A2 based whole-cell system in Escherichia coli for the biotechnological production of premedrol.","date":"2015","source":"Microbial cell factories","url":"https://pubmed.ncbi.nlm.nih.gov/26374204","citation_count":20,"is_preprint":false},{"pmid":"37276943","id":"PMC_37276943","title":"Long-read sequencing: An effective method for genetic analysis of CYP21A2 variation in congenital adrenal hyperplasia.","date":"2023","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37276943","citation_count":20,"is_preprint":false},{"pmid":"22020670","id":"PMC_22020670","title":"Clinical phenotype and mutation spectrum of the CYP21A2 gene in patients with steroid 21-hydroxylase deficiency.","date":"2011","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/22020670","citation_count":19,"is_preprint":false},{"pmid":"9888552","id":"PMC_9888552","title":"Allele-dropout using PCR-based diagnosis for the splicing mutation in intron-2 of the CYP21B-gene: successful amplification with a Taq/Pwo-polymerase mixture.","date":"1998","source":"Endocrine research","url":"https://pubmed.ncbi.nlm.nih.gov/9888552","citation_count":18,"is_preprint":false},{"pmid":"9881898","id":"PMC_9881898","title":"Mutations of the CYP21 gene in nonclassical steroid 21-hydroxylase deficiency in Japan.","date":"1998","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/9881898","citation_count":18,"is_preprint":false},{"pmid":"15775714","id":"PMC_15775714","title":"Molecular analysis of the CYP21 gene and prenatal diagnosis in families with 21-hydroxylase deficiency in northeastern Iran.","date":"2005","source":"Hormone research","url":"https://pubmed.ncbi.nlm.nih.gov/15775714","citation_count":17,"is_preprint":false},{"pmid":"24503005","id":"PMC_24503005","title":"Molecular analysis of the CYP21A2 gene in Chinese patients with steroid 21-hydroxylase deficiency.","date":"2014","source":"Clinical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24503005","citation_count":17,"is_preprint":false},{"pmid":"12788880","id":"PMC_12788880","title":"Mutation of IVS2 -12A/C>G in combination with 707-714delGAGACTAC in the CYP21 gene is caused by deletion of the C4-CYP21 repeat module with steroid 21-hydroxylase deficiency.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12788880","citation_count":16,"is_preprint":false},{"pmid":"32131114","id":"PMC_32131114","title":"Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: An Update on Genetic Analysis of CYP21A2 Gene.","date":"2020","source":"Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association","url":"https://pubmed.ncbi.nlm.nih.gov/32131114","citation_count":16,"is_preprint":false},{"pmid":"22561756","id":"PMC_22561756","title":"Vitamin D-mediated regulation of CYP21A2 transcription - a novel mechanism for vitamin D action.","date":"2012","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22561756","citation_count":16,"is_preprint":false},{"pmid":"25538881","id":"PMC_25538881","title":"Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations.","date":"2014","source":"Indian journal of endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/25538881","citation_count":16,"is_preprint":false},{"pmid":"15684714","id":"PMC_15684714","title":"Diversity of the CYP21P-like gene in CYP21 deficiency.","date":"2005","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15684714","citation_count":15,"is_preprint":false},{"pmid":"1551657","id":"PMC_1551657","title":"CYP21/C4 gene organisation in Italian 21-hydroxylase deficiency families.","date":"1992","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1551657","citation_count":15,"is_preprint":false},{"pmid":"1677925","id":"PMC_1677925","title":"Extended MHC haplotypes and CYP21/C4 gene organisation in Irish 21-hydroxylase deficiency families.","date":"1991","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1677925","citation_count":15,"is_preprint":false},{"pmid":"24823785","id":"PMC_24823785","title":"Mutational analysis of CYP21A2 gene and CYP21A1P pseudogene: long-range PCR on genomic DNA.","date":"2014","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/24823785","citation_count":15,"is_preprint":false},{"pmid":"17573904","id":"PMC_17573904","title":"Three novel CYP21A2 mutations and their protein modelling in patients with classical 21-hydroxylase deficiency from northeastern Iran.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17573904","citation_count":15,"is_preprint":false},{"pmid":"11739005","id":"PMC_11739005","title":"Multiple transcripts of the CYP21 gene are generated by the mutation of the splicing donor site in intron 2 from GT to AT in 21-hydroxylase deficiency.","date":"2001","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11739005","citation_count":15,"is_preprint":false},{"pmid":"31404637","id":"PMC_31404637","title":"Fine-mapping of the substrate specificity of human steroid 21-hydroxylase (CYP21A2).","date":"2019","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/31404637","citation_count":15,"is_preprint":false},{"pmid":"26233337","id":"PMC_26233337","title":"Molecular genetic study of congenital adrenal hyperplasia in Serbia: novel p.Leu129Pro and p.Ser165Pro CYP21A2 gene mutations.","date":"2015","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26233337","citation_count":15,"is_preprint":false},{"pmid":"1978247","id":"PMC_1978247","title":"Exon 7 Ncol restriction site within CYP21B (steroid 21-hydroxylase) is a normal polymorphism.","date":"1990","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/1978247","citation_count":14,"is_preprint":false},{"pmid":"9518489","id":"PMC_9518489","title":"The -104G nucleotide of the human CYP21 gene is important for CYP21 transcription activity and protein interaction.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9518489","citation_count":14,"is_preprint":false},{"pmid":"9132494","id":"PMC_9132494","title":"Characterisation of CAH alleles with non-radioactive DNA single strand conformation polymorphism analysis of the CYP21 gene.","date":"1997","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9132494","citation_count":14,"is_preprint":false},{"pmid":"10471376","id":"PMC_10471376","title":"Functional analysis of four CYP21 mutations from spanish patients with congenital adrenal hyperplasia.","date":"1999","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/10471376","citation_count":14,"is_preprint":false},{"pmid":"28487735","id":"PMC_28487735","title":"Variations in the 3'UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia.","date":"2017","source":"International journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28487735","citation_count":14,"is_preprint":false},{"pmid":"22217838","id":"PMC_22217838","title":"Comparison of cAMP-responsive DNA sequences and their binding proteins associated with expression of the bovine CYP17 and CYP11A and human CYP21B genes.","date":"1992","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22217838","citation_count":13,"is_preprint":false},{"pmid":"16028060","id":"PMC_16028060","title":"Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16028060","citation_count":13,"is_preprint":false},{"pmid":"31393570","id":"PMC_31393570","title":"Carriers of a Classic CYP21A2 Mutation Have Reduced Mortality: A Population-Based National Cohort Study.","date":"2019","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31393570","citation_count":13,"is_preprint":false},{"pmid":"35363313","id":"PMC_35363313","title":"Long-read Amplicon Sequencing of the CYP21A2 in 48 Thai Patients With Steroid 21-Hydroxylase Deficiency.","date":"2022","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/35363313","citation_count":13,"is_preprint":false},{"pmid":"23142378","id":"PMC_23142378","title":"Investigation of CYP21A2 mutations in Turkish patients with 21-hydroxylase deficiency and a novel founder mutation.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23142378","citation_count":13,"is_preprint":false},{"pmid":"20818501","id":"PMC_20818501","title":"Identification of CYP21A2 mutant alleles in Czech patients with 21-hydroxylase deficiency.","date":"2010","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20818501","citation_count":13,"is_preprint":false},{"pmid":"18445671","id":"PMC_18445671","title":"Functional and structural consequences of a novel point mutation in the CYP21A2 gene causing congenital adrenal hyperplasia: potential relevance of helix C for P450 oxidoreductase-21-hydroxylase interaction.","date":"2008","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/18445671","citation_count":13,"is_preprint":false},{"pmid":"28521877","id":"PMC_28521877","title":"CYP21A2 intronic variants causing 21-hydroxylase deficiency.","date":"2017","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/28521877","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52281,"output_tokens":5455,"usd":0.119334,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13898,"output_tokens":4066,"usd":0.08557,"stage2_stop_reason":"end_turn"},"total_usd":0.204904,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1988,\n      \"finding\": \"A missense mutation in CYP21B (Ile-172→Asn, codon 172 ATC→AAC) causes steroid 21-hydroxylase deficiency; the mutant gene is expressed in transfected mouse Y1 adrenal cells and produces mRNA but an enzymatically deficient protein, establishing this as a loss-of-function coding mutation.\",\n      \"method\": \"Site-directed mutagenesis, transfection into mouse Y1 adrenal cells, mRNA expression analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct expression in adrenal cells with functional consequence, foundational result replicated in many subsequent studies\",\n      \"pmids\": [\"3257825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"A 34-nucleotide sequence (-129/-96 bp) in the 5'-flanking region of the human CYP21B gene is required for cAMP-dependent transcription; this element is distinct from the consensus CRE and binds a nuclear protein from adrenal (but not non-adrenal) cells in gel retardation assays, indicating an adrenal-specific transcription factor drives cAMP-dependent CYP21B expression.\",\n      \"method\": \"Chimeric reporter gene transfection assays (CAT, β-globin reporters), gel retardation/EMSA, cycloheximide inhibition experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter assays, EMSA, protein synthesis inhibitor), replicated in subsequent studies (PMID:1645728, PMID:1334085)\",\n      \"pmids\": [\"2162843\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1991,\n      \"finding\": \"The cAMP-responsive element of CYP21B (-129/-96 bp) contains two overlapping protein-binding sites: one (-126/-113 bp) binds an adrenal-specific protein (ASP) and the other (-119/-110 bp) binds Sp1. The G→C substitution at -113/-112 bp abolishes binding of both ASP and Sp1 and eliminates cAMP-enhanced transcription. The -126/-113 bp ASP-binding sequence alone is sufficient to confer cAMP-inducible transcription and is functionally conserved in the bovine CYP21B gene.\",\n      \"method\": \"Gel shift assays (EMSA), site-directed mutagenesis, transient transfection reporter assays, competition analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal EMSA and mutagenesis with functional reporter assay readout in the same study; independently replicated in PMID:1334085\",\n      \"pmids\": [\"1645728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"ASP, the adrenal-specific 78 kDa transcription factor binding the CYP21B cAMP-responsive element (-126/-113 bp), was purified by sequence-specific DNA-affinity chromatography. Antibody against ASP supershifts the DNA-ASP complex and inhibits in vitro transcription. Purified ASP enhances mRNA synthesis from the minimum CRE in a cell-free system, whereas Sp1 does not, establishing ASP as the primary transcription factor for cAMP-dependent CYP21B regulation.\",\n      \"method\": \"DNA-affinity chromatography purification, EMSA supershift, in vitro transcription assay, DNase I footprinting, SDS-PAGE\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protein purification, in vitro reconstitution of transcription, footprinting, and antibody inhibition in one study\",\n      \"pmids\": [\"1334085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The cAMP-responsive sequences (CRS) of CYP21B and CYP17 are distinct from each other and from known CRE consensus sequences; CYP21B CRS binds a putative adrenal-specific nuclear protein, while CYP17 CRSI binds a ubiquitous protein active only in steroidogenic cells, demonstrating that ACTH-dependent co-regulation of these two steroid hydroxylase genes operates through distinct biochemical mechanisms.\",\n      \"method\": \"Deletion analysis of upstream regulatory regions, nuclear protein binding assays\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — binding assays and deletion analysis, single lab, corroborates PMID:2162843 and PMID:1645728\",\n      \"pmids\": [\"1311271\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CYP21A2 (CYP21B) encodes a microsomal cytochrome P450 enzyme expressed in the adrenal gland that catalyzes conversion of 17-hydroxyprogesterone to 11-deoxycortisol and progesterone to deoxycorticosterone; the degree of enzymatic compromise caused by each mutation is correlated with clinical severity of disease.\",\n      \"method\": \"Review synthesizing transfection/expression studies and biochemical characterization; genotype-phenotype correlation across patient cohorts\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic function established by in vitro expression systems across multiple labs; summarized here but underpinned by replicated biochemical experiments\",\n      \"pmids\": [\"8081391\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"De novo deletions of CYP21 (approximately 30 kb, breakpoints in intron 2/exon 3) are detected in sperm but not matched leukocyte DNA, occurring at frequencies of ~1/10^5–10^6 genomes, establishing they arise exclusively during meiosis. Gene conversions in the same region occur in both sperm and leukocyte DNA (~1/10^3–10^5 genomes), indicating gene conversions occur during mitosis (or both meiosis and mitosis), a distinct mechanism from unequal crossing-over.\",\n      \"method\": \"PCR detection of de novo events in matched sperm and leukocyte DNA from normal individuals\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct comparison of sperm vs. somatic DNA with quantitative frequency estimates; mechanistically distinguishes two recombination mechanisms\",\n      \"pmids\": [\"7479886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The -104G nucleotide in the CYP21 promoter (differing from the CYP21P pseudogene sequence) is required for basal transcription activity; changing -104G to the CYP21P sequence decreases basal transcription by ~80% in transfection assays and abolishes interaction with nuclear proteins from adrenal cells in gel-shift assays.\",\n      \"method\": \"Transient transfection reporter assay, site-directed mutagenesis, EMSA with adrenal nuclear extracts\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — mutagenesis combined with reporter assay and EMSA, single lab\",\n      \"pmids\": [\"9518489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Several novel CYP21 mutations (G90V, G291C, R354H, G178A) were functionally characterized by transient transfection in CHOP cells: G90V, G291C, and R354H effectively eliminated 21-hydroxylase activity toward both progesterone and 17α-hydroxyprogesterone, consistent with severe salt-wasting disease; G178A retained significant activity with 17α-hydroxyprogesterone, correlating with the milder simple virilizing phenotype.\",\n      \"method\": \"In vitro enzyme activity assay in transiently transfected CHOP cells with radiolabeled substrates (progesterone, 17α-hydroxyprogesterone)\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct in vitro enzyme assay with two substrates, single lab\",\n      \"pmids\": [\"10471376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The IVS2+1G→A splice donor mutation in CYP21 causes generation of two aberrant transcripts when the genomic construct is transfected into COS-1 cells: one lacking exon 2 entirely, and one (~30% of transcripts) with inclusion of 3' intron 2 sequences due to use of a cryptic splice acceptor site, resulting in a non-functional protein.\",\n      \"method\": \"Transfection of CYP21 genomic construct into COS-1 cells, RT-PCR analysis of transcripts\",\n      \"journal\": \"The Journal of endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct transcript analysis after transfection, single lab, mechanistically defines splicing consequences of IVS2+1G→A\",\n      \"pmids\": [\"11739005\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The novel CYP21 missense mutation V304M shows 46% residual enzyme activity for 17-hydroxyprogesterone and 26% for progesterone conversion in COS-1 cells, with normal protein degradation, indicating a functional rather than structural defect consistent with nonclassical disease. G375S nearly abolishes enzyme activity (1.6% and 0.7% of normal for both substrates), consistent with classical disease.\",\n      \"method\": \"In vitro enzyme activity assay in transiently transfected COS-1 cells with both natural substrates; protein degradation analysis\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct in vitro enzyme assay with two substrates plus protein stability assessment, single lab\",\n      \"pmids\": [\"12050257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Four novel CYP21 missense mutations (L166P, A391T, R479L, R483Q) were characterized by in vitro enzyme assay in transiently transfected mammalian cells; all showed reduced activity compared to wild-type for both natural substrates (17-hydroxyprogesterone and progesterone), spanning the full spectrum of disease severity from severe to mild.\",\n      \"method\": \"In vitro enzyme activity assay in transfected mammalian cells with radiolabeled 17-hydroxyprogesterone and progesterone\",\n      \"journal\": \"Journal of molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct enzyme assay with two substrates, single lab\",\n      \"pmids\": [\"17119906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Microconversions between the CYP21A2 and CYP21A1P promoter regions (-126C>T, -113G>A, -110T>C) reduce CYP21A2 transcriptional activity to 52% of wild-type in luciferase reporter assays, contributing to the nonclassical CAH phenotype. EMSA demonstrated that the -132/-121 region is critical for interaction with the Sp1 transcription factor.\",\n      \"method\": \"Luciferase reporter transfection assays, EMSA with NCI-H295A nuclear extracts and wild-type/mutant probes, direct DNA sequencing\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — orthogonal reporter assay and EMSA, single lab\",\n      \"pmids\": [\"17666484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Three novel CYP21A2 mutations (p.G56R, p.L107R, p.L142P) and one recurrent mutation (p.R408C) were characterized by in vitro activity assay in transiently transfected COS-1 cells; all showed very low residual activity (<5% for both substrates), classifying them as classical CAH mutations. p.H62L showed activity within the nonclassical range; p.H62L+p.P453S in combination showed a synergistic reduction in activity greater than either alone.\",\n      \"method\": \"In vitro enzyme activity assay in transiently transfected COS-1 cells; apparent kinetic constants (Km) determined for H62L mutant\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — kinetic characterization plus activity assay with two substrates, single lab\",\n      \"pmids\": [\"18381579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The novel CYP21A2 mutation K121Q (located on helix C) reduces 21-hydroxylase activity to ~14–19% of normal in transfected COS-7 cells. Protein modeling reveals K121 is in the heme-coordinating system and on the surface involved in P450 oxidoreductase interaction, suggesting the mutation impairs electron flux from P450 oxidoreductase to CYP21A2 and alters substrate affinity via heme dislocation.\",\n      \"method\": \"In vitro expression in transiently transfected COS-7 cells, homology-based 3D protein modeling\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct in vitro enzyme assay plus structural modeling, single lab; modeling is computational but supports mechanistic inference\",\n      \"pmids\": [\"18445671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"p.H62L alone reduces CYP21 enzyme activity similarly to the mild p.P453S mutation (nonclassical range); when p.H62L is combined with p.P453S on the same allele, enzymatic activity is synergistically reduced to a level intermediate between p.P453S and p.I172N. 3D modeling locates H62 in a domain involved in membrane anchoring.\",\n      \"method\": \"In vitro enzyme activity assay in transfected cells; 3D protein model analysis; phenotype correlation\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct enzyme assay demonstrating synergistic effect, single lab\",\n      \"pmids\": [\"18319307\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"1α,25-Dihydroxyvitamin D3 suppresses CYP21A2 transcription via a vitamin D receptor (VDR)-mediated mechanism. A vitamin D response element was identified in the CYP21A2 promoter; interaction of this element with VDR, WSTF, and VDIR comodulators was confirmed by chromatin immunoprecipitation. Deletion of this element abolished the vitamin D effect; siRNA knockdown of VDIR confirmed its involvement. An altered balance of comodulators can reverse the suppressive effect to stimulatory.\",\n      \"method\": \"Luciferase reporter assays with promoter deletion constructs, chromatin immunoprecipitation (ChIP), site-directed mutagenesis, siRNA knockdown\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (reporter assay, ChIP, mutagenesis, siRNA) in a single study\",\n      \"pmids\": [\"22561756\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Using a humanized homology model of CYP21A2 based on the bovine crystal structure, CYP21A2 mutations causing complete loss of function (salt-wasting disease) affect membrane anchoring, heme/substrate binding, or protein stability; mutations causing simple virilizing disease alter the transmembrane region or conserved hydrophobic patches (up to 98% activity reduction); mild nonclassical disease results from interference with oxidoreductase interactions, salt-bridge/hydrogen-bonding networks, or nonconserved hydrophobic clusters.\",\n      \"method\": \"Computational structure-function modeling based on bovine CYP21 crystal structure; comprehensive mapping of >100 disease-causing mutations onto 3D model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — structural/computational model with systematic coverage of >100 mutations correlated to known biochemical activity data; no direct in vitro validation of new mutations in this paper\",\n      \"pmids\": [\"23359706\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A CYP21A2-based whole-cell biocatalytic system in E. coli (co-expressing bovine CYP21A2 with NADPH-dependent cytochrome P450 reductase, CPR, via a bicistronic vector) selectively 21-hydroxylates the synthetic substrate medrane to premedrol, demonstrating that CYP21A2 requires CPR as its redox partner for electron supply, and that the catalytic yield is directly dependent on the efficiency of the electron transfer system.\",\n      \"method\": \"Whole-cell biotransformation in E. coli; bicistronic co-expression of CYP21A2 and CPR; comparison of five alternative redox systems; bioreactor optimization\",\n      \"journal\": \"Microbial cell factories\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted enzymatic system with defined redox partner, multiple redox partner comparisons, bioreactor validation\",\n      \"pmids\": [\"26374204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CYP21A2 requires a 3-oxo group at C-3 of the steroid substrate as a strict requirement for catalytic activity; all other ring A configurations tested (hydroxyl, oxo, fluoro, chloro groups; presence/absence of Δ1 and Δ4 double bonds; heteroatoms) were tolerated. Progesterone and 17-hydroxyprogesterone are hydroxylated at C-21, whereas (17-hydroxy-)pregnenolone (lacking the 3-oxo group) is not a substrate. Molecular docking suggests the C-3 carbonyl interacts indispensably with Arg234 in the active site.\",\n      \"method\": \"In vitro enzyme activity assay with sixteen synthetic 17,17-dimethyl-18-nor-13-ene steroid substrates plus endogenous steroids; molecular docking\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — comprehensive substrate specificity mapping with 16+ substrates in biochemical assay plus structural docking, single lab but multiple orthogonal lines of evidence\",\n      \"pmids\": [\"31404637\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP21A2 encodes a microsomal cytochrome P450 enzyme that catalyzes the NADPH-dependent (via P450 oxidoreductase as its electron donor) 21-hydroxylation of progesterone to deoxycorticosterone and 17-hydroxyprogesterone to 11-deoxycortisol in the adrenal cortex; catalysis requires a 3-oxo group at C-3 of the substrate, which interacts with active-site residue Arg234; adrenal-specific, cAMP-dependent transcription is driven by an adrenal-specific 78 kDa transcription factor (ASP) binding a unique promoter element (-126/-113 bp), with Sp1 as a co-occupant, and is further modulated by 1α,25-dihydroxyvitamin D3 through a VDR/VDIR/WSTF comodulator mechanism at a distinct promoter response element; disease-causing mutations spanning salt-wasting to nonclassical phenotypes act by disrupting membrane anchoring, heme/substrate binding, protein stability, oxidoreductase interaction surfaces, or structural integrity of the active site.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP21A2 encodes a microsomal cytochrome P450 enzyme of the adrenal cortex that catalyzes the 21-hydroxylation of progesterone to deoxycorticosterone and of 17-hydroxyprogesterone to 11-deoxycortisol, the committed step routing steroid precursors toward mineralocorticoid and glucocorticoid synthesis [#5]. Catalysis depends on a strict structural requirement of the substrate—a 3-oxo group at C-3 of ring A, which docking places in indispensable contact with the active-site residue Arg234, while other ring A configurations are tolerated [#19]. The enzyme operates as the terminal oxidase of a two-component system, drawing electrons from NADPH-dependent cytochrome P450 reductase (CPR) as its obligate redox partner, with catalytic output scaling directly with electron-transfer efficiency [#18]. Adrenal-restricted, cAMP-responsive transcription is driven through a unique promoter element (-126/-113 bp) bound by a purified 78 kDa adrenal-specific protein (ASP), which alone is sufficient to confer cAMP-inducible transcription and to enhance mRNA synthesis in vitro, with Sp1 occupying an overlapping adjacent site [#2, #3]; transcription is further modulated by 1\\u03b1,25-dihydroxyvitamin D3 through a promoter response element engaging VDR, WSTF, and VDIR comodulators [#16]. Loss-of-function mutations across the gene cause steroid 21-hydroxylase deficiency, and the degree of enzymatic compromise measured in expression assays correlates with clinical severity from salt-wasting through simple virilizing to nonclassical phenotypes [#5, #0]; structure-function mapping attributes these effects to disruption of membrane anchoring, heme/substrate binding, protein stability, oxidoreductase interaction surfaces, or active-site integrity [#17].\",\n  \"teleology\": [\n    {\n      \"year\": 1988,\n      \"claim\": \"Established that a single coding missense change in CYP21 produces a stable but catalytically deficient enzyme, defining 21-hydroxylase deficiency as a loss-of-function disorder rather than a regulatory or expression defect.\",\n      \"evidence\": \"Site-directed mutagenesis of Ile-172\\u2192Asn expressed in transfected mouse Y1 adrenal cells with mRNA and activity analysis\",\n      \"pmids\": [\"3257825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve which structural feature of the enzyme the residue maintains\", \"Single mutation; spectrum of allelic effects not yet mapped\"]\n    },\n    {\n      \"year\": 1990,\n      \"claim\": \"Identified the cis element responsible for adrenal-specific, cAMP-driven CYP21 expression, showing it is distinct from canonical CRE and bound by an adrenal-restricted nuclear factor.\",\n      \"evidence\": \"Chimeric reporter transfection, EMSA with adrenal vs. non-adrenal extracts, and cycloheximide inhibition\",\n      \"pmids\": [\"2162843\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding factor not yet purified or identified\", \"Relationship to general cAMP signaling machinery unresolved\"]\n    },\n    {\n      \"year\": 1991,\n      \"claim\": \"Dissected the cAMP-responsive region into overlapping ASP and Sp1 binding sites and showed the ASP site alone suffices for cAMP induction, separating the adrenal-specific factor from the ubiquitous Sp1.\",\n      \"evidence\": \"EMSA, site-directed mutagenesis (G\\u2192C at -113/-112), and competition reporter assays, with bovine conservation\",\n      \"pmids\": [\"1645728\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ASP identity remained unknown\", \"Mechanistic link between cAMP signaling and ASP activity not defined\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Purified the 78 kDa adrenal-specific protein ASP and demonstrated it directly drives transcription from the minimal CRE in a cell-free system, establishing it as the primary determinant of cAMP-dependent CYP21 regulation over Sp1.\",\n      \"evidence\": \"DNA-affinity purification, EMSA supershift, in vitro transcription, DNase I footprinting; parallel deletion analysis distinguishing CYP21 from CYP17 regulation\",\n      \"pmids\": [\"1334085\", \"1311271\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Gene encoding ASP not cloned\", \"Signaling cascade coupling ACTH/cAMP to ASP function unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Consolidated CYP21A2 as a microsomal adrenal P450 converting progesterone and 17-hydroxyprogesterone, and articulated the genotype-phenotype principle that residual enzymatic activity predicts disease severity.\",\n      \"evidence\": \"Review synthesizing transfection/expression and biochemical studies with cohort genotype-phenotype correlation\",\n      \"pmids\": [\"8081391\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of activity loss for individual mutations not yet defined\", \"Redox partner requirement not directly demonstrated\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Distinguished the two mutational mechanisms underlying CYP21 deficiency, showing large deletions arise in meiosis while gene conversions also occur mitotically.\",\n      \"evidence\": \"PCR detection of de novo events in matched sperm vs. leukocyte DNA from normal individuals with frequency estimation\",\n      \"pmids\": [\"7479886\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants of recombination hotspots not defined\", \"Does not address point mutation origins\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed that a single promoter nucleotide distinguishing CYP21A2 from its pseudogene controls basal transcription and adrenal nuclear protein binding, linking pseudogene-derived microconversions to expression defects.\",\n      \"evidence\": \"Reporter assay, site-directed mutagenesis, and EMSA with adrenal extracts\",\n      \"pmids\": [\"9518489\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Identity of the bound nuclear protein not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstrated that mutations can impair catalysis without destabilizing the protein, defining a functional (active-site) versus structural (degradation) basis for milder versus severe phenotypes.\",\n      \"evidence\": \"In vitro activity assays with both substrates plus protein degradation analysis in COS-1 cells (V304M vs. G375S)\",\n      \"pmids\": [\"12050257\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Limited to two mutations\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped specific mutations to functional domains—membrane anchoring, the heme-coordinating system, and the P450 oxidoreductase interaction surface—and revealed synergistic activity loss when mild variants co-occur in cis.\",\n      \"evidence\": \"In vitro activity/kinetic assays in COS cells combined with homology-based 3D modeling (K121Q, H62L, P453S and others)\",\n      \"pmids\": [\"18445671\", \"18319307\", \"18381579\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Modeling-based domain assignments not directly validated biochemically\", \"Single-lab activity measurements\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified vitamin D as a transcriptional modulator of CYP21A2, acting through a defined promoter response element and VDR/WSTF/VDIR comodulators whose balance can switch the effect between repressive and stimulatory.\",\n      \"evidence\": \"Reporter deletion constructs, ChIP, site-directed mutagenesis, and VDIR siRNA knockdown\",\n      \"pmids\": [\"22561756\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological significance of vitamin D regulation in vivo not established\", \"Interplay with the cAMP/ASP axis unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Provided a unifying structural framework correlating mutation location with phenotype, attributing salt-wasting, simple virilizing, and nonclassical disease to distinct classes of structural perturbation.\",\n      \"evidence\": \"Computational structure-function mapping of >100 mutations onto a humanized homology model from the bovine CYP21 crystal structure\",\n      \"pmids\": [\"23359706\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct in vitro validation of newly classified mutations in this work\", \"Predictions for individual variants require experimental confirmation\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Defined the obligate redox dependency of CYP21A2 by reconstituting catalysis with CPR and showing that yield tracks electron-transfer efficiency, confirming CPR as the physiological electron donor.\",\n      \"evidence\": \"Whole-cell E. coli biotransformation with bicistronic CYP21A2/CPR co-expression and comparison of five redox systems\",\n      \"pmids\": [\"26374204\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Performed with bovine enzyme and a synthetic substrate\", \"Quantitative coupling parameters in native adrenal microsomes not measured\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined the precise substrate determinant of catalysis—an obligatory C-3 oxo group engaging Arg234—explaining why progesterone and 17-hydroxyprogesterone are substrates while pregnenolone is not.\",\n      \"evidence\": \"In vitro activity assays with 16 synthetic steroid analogs plus endogenous steroids and molecular docking\",\n      \"pmids\": [\"31404637\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Arg234 contact inferred from docking, not crystallography\", \"Catalytic mechanism of hydroxyl transfer not directly resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The molecular identity of the adrenal-specific transcription factor ASP and how ACTH/cAMP signaling is mechanistically transduced to activate it remain unresolved in the available corpus.\",\n      \"evidence\": \"No discovery cloning or molecularly identifying ASP is present in the timeline\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"ASP gene not identified\", \"Signaling pathway from cAMP to ASP activity undefined\", \"No experimental crystal structure of human CYP21A2\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [5, 18, 19]},\n      {\"term_id\": \"GO:0005506\", \"supporting_discovery_ids\": [14, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [5, 19]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"POR\",\n      \"SP1\",\n      \"VDR\",\n      \"VDIR\",\n      \"WSTF\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":5,"faith_total":5,"faith_pct":100.0}}